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INTRODUCTION
Hyponatremia is defined as a decrease in the serum sodium 
concentration to a level less than 134 mmol/L. Hyponatremia is 
a reported complication of treatment with antidepressant drugs 
such as selective serotonin reuptake inhibitors (SSRIs), includ-
ing fluoxetine and sertraline, and the dual-action antidepres-
sant venlafaxine.
1,2
Duloxetine is a relatively balanced selective serotonin and nor-
adrenaline reuptake inhibitor (SNRI), which is approved for the 
treatment of major depressive disorder, generalized anxiety dis-
order, and diabetic peripheral neuropathic pain. The most fre-
quently reported adverse events with duloxetine include nau-
sea (20%), dry mouth (16%), fatigue (11%), dizziness (11%), con-
stipation (11%), somnolence (8%), decreased appetite (6%), and 
increased sweating (5%).
3 In rare cases, hyponatremia induced 
by duloxetine has been reported in patients with depression
4-6 
and neuropathic pain.
7 However, most cases have involved elder-
ly female patients (66 or 85 years old);
5,6 there is no report of hy-
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ponatremia associated with duloxetine in middle-aged males 
with depression as well as multiple somatic symptoms. 
CASE
A 58-year-old male patient was admitted with multiple so-
matic symptoms: chiefly, a tingling sense and pain in all four ex-
tremities and a foreign body sensation in the throat. In addition, 
he showed anxiety, depressed mood, sleep disturbance, decreased 
oral intake, and weight loss. To evaluate his somatic symptoms, 
he had undergone nerve conduction studies, electromyography, 
neck computed tomography (CT), abdomen/chest CT, brain 
magnetic resonance imaging (MRI), and blood tests. No abnor-
malities were found. Immediately after this evaluation, he de-
veloped a high fever and leukocytosis. Pneumonia was diagnosed 
based on a physical examination and chest x-ray. After admin-
istering antibiotics (amikacin sulfate), his vital signs and leuko-
cytosis normalized. Then, on hospital day 5, duloxetine 30 mg 
daily was initiated for the multiple somatic symptoms and de-
pressive symptoms. His serum sodium level on that day was 
135.1 mmol/L. The serum sodium the next day was 130 mmol/
L. Three days after initiating the duloxetine, his serum sodium 
decreased to 127 mmol/L. Since his presenting somatic symp-
toms had not changed and he did not show any other adverse 
events, the dose of duloxetine was increased to 60 mg daily 5 
days after initiating the duloxetine. The next day, the serum so-
dium level had decreased to 122 mmol/L. The serum osmolari-
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ty was 263 mOsm/kg, and the urine osmolarity was 394 mOsm/
kg, with a urine sodium of 81.4 mmol/L. Thyroid function tests 
and the cortisol level were normal. The syndrome of inappropri-
ate antidiuretic hormone (SIADH) was diagnosed based on the 
presence of hyponatremia, hypo-osmolarity, increased urine 
osmolarity, and increased urine sodium level. The duloxetine 
was discontinued and the patient was managed with hyperton-
ic saline and fluid restriction. Two days after discontinuing the 
duloxetine, the serum sodium level had normalized to 135.4 
mmol/L. 
DISCUSSION
Our patient developed hyponatremia within 1 week of ad-
ministering duloxetine for multiple somatic symptoms and de-
pressive symptoms. The cause of the hyponatremia was con-
sidered to be SIADH. However, the mechanism of SIADH as-
sociated with an SSRI or SNRI is unclear. Roxanas
8 postulated 
that hyponatremia associated with an SSRI might be related to 
the serotonergic stimulation of antidiuretic hormone (ADH) 
production. Arinzon et al.
9 also suggested that SSRI-induced 
SIADH is multifactorial, including an increase in the secretion 
of ADH centrally, augmentation of the effect of ADH in the re-
nal medulla, a resetting of the osmostat that lowers the thresh-
old for secretion, and an interaction with other drugs. 
In this case, there were several distinct findings associated 
with the hyponatremia induced by duloxetine. First, the patient 
was male and was not elderly. Previous reports of duloxetine-
induced hyponatremia have been in elderly females.
5-7 In ad-
dition, hyponatremia from SSRI use has been reported in elder-
ly females predominantly.
8-10 Second, the hyponatremia began 
1 day after duloxetine administration. The hyponatremia relat-
ed to SSRI use developed 2 to 3 weeks following the start of the 
drug,
11,12 while the hyponatremia induced by duloxetine devel-
oped more rapidly. Previous reports described hyponatremia 
developing after 2 or 3 days of duloxetine therapy, which con-
curs with our report.
7,13 Third, the patient had two risk factors 
for developing hyponatremia: lower body weight and pneumo-
nia. The risk factors for hyponatremia include older age, female, 
history of hyponatremia, lower body mass index (BMI), use of 
thiazide diuretics, lower baseline serum sodium level (<138 
mmol/L), and significant comorbidities.
11,14-16 Especially, Fabi-
an et al.
11 suggested that a lower BMI was a significant risk fac-
tor for developing hyponatremia associated with SSRI use. 
Our patient had a BMI of 15.2 on admission. Furthermore, the 
patient had pneumonia before beginning the duloxetine ther-
apy. These factors may have precipitated the duloxetine-induced 
hyponatremia.
In summary, hyponatremia induced by duloxetine devel-
oped rapidly after starting the medication in a middle-aged 
male with multiple somatic symptoms and depression. Two risk 
factors - severe body weight loss and pneumonia - may have 
made him more vulnerable to developing hyponatremia. There-
fore, when treating patients with depression and somatic symp-
toms, especially with risk factors for developing hyponatremia, 
close monitoring for clinical and laboratory evidence of hypo-
natremia is essential. 
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